Sirolimus lowers NMSC risk in transplant recipients
from Renal & Urology News
Switching from a calcineurin inhibitor (CNI) to sirolimus for immunosuppression may decrease the risk of nonmelanoma skin cancer (NMSC) in kidney transplant recipients with a history of NMSC, according to researchers.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063